Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast Thomas JohnMargarita MajemJonathan Goldman Commentary Open access 19 December 2022 Pages: 1 - 8
Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies Sanjay PopatMyung-Ju AhnJames Chih-Hsin Yang Review Article 18 January 2023 Pages: 9 - 24
Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management Houssein SafaFawzi Abu RousBalazs Halmos Review Article 29 December 2022 Pages: 25 - 49
Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective Cindy NeuzilletPascal ArtruDavid Malka Review Article Open access 06 February 2023 Pages: 51 - 76
Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma Julia BalaguerLaura García HidalgoVanesa Pérez Alonso Review Article Open access 12 December 2022 Pages: 77 - 93
Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases Gordon BrownLaurence BelkoffNeal D. Shore Original Research Article Open access 06 December 2022 Pages: 95 - 103
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors Christian KollmannsbergerHerbert HurwitzGeoffrey I. Shapiro Original Research Article 02 December 2022 Pages: 105 - 118
Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study Yosuke KorokiMasataka Taguri Original Research Article Open access 28 November 2022 Pages: 119 - 128
Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy Antonello VecciaMariachiara DipasqualeOrazio Caffo Original Research Article Open access 08 December 2022 Pages: 129 - 138
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients Margherita RiminiCarles Fabregat-FrancoAndrea Casadei-Gardini Original Research Article 23 January 2023 Pages: 139 - 145
Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis Su Jeong SongYun-Kyoung SongJung Mi Oh Original Research Article 14 December 2022 Pages: 147 - 158
Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma Hiroki IshiharaYuki NemotoToshio Takagi Original Research Article 26 December 2022 Pages: 159 - 168
Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC Tina NieYahiya Y. Syed Adis Drug Evaluation 24 November 2022 Pages: 169 - 176
Correction to: Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer Arnold Lee Correction Open access 02 December 2022 Pages: 177 - 177
Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan Yen-Hsiang HuangKuo-Hsuan HsuGee-Chen Chang Correction Open access 05 November 2022 Pages: 179 - 180